Values First Advisors Inc. Has $607,000 Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Values First Advisors Inc. increased its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 49.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 89,775 shares of the company’s stock after acquiring an additional 29,552 shares during the period. Values First Advisors Inc.’s holdings in Recursion Pharmaceuticals were worth $607,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. Exchange Traded Concepts LLC raised its stake in shares of Recursion Pharmaceuticals by 24.9% during the 3rd quarter. Exchange Traded Concepts LLC now owns 25,182 shares of the company’s stock worth $166,000 after purchasing an additional 5,021 shares in the last quarter. Vontobel Holding Ltd. acquired a new position in Recursion Pharmaceuticals in the third quarter worth approximately $70,000. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its stake in Recursion Pharmaceuticals by 104.6% in the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 82,352 shares of the company’s stock valued at $543,000 after acquiring an additional 42,101 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in Recursion Pharmaceuticals in the third quarter valued at approximately $25,000. Finally, Foundations Investment Advisors LLC increased its stake in shares of Recursion Pharmaceuticals by 25.0% during the 3rd quarter. Foundations Investment Advisors LLC now owns 193,036 shares of the company’s stock worth $1,272,000 after purchasing an additional 38,642 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th. KeyCorp reduced their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX opened at $8.34 on Thursday. Recursion Pharmaceuticals, Inc. has a 12 month low of $5.60 and a 12 month high of $15.74. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The company’s 50 day moving average is $7.19 and its 200-day moving average is $6.89.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.